Clinical Trial Update: The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial investigating the optimal timing of a second autologous peripheral blood stem cell transplantation in patients under 61 years with mult…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Centre National de Greffe de Moelle Osseuse | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED